Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

about

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q47093485

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@en

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@nl

type

Item

label

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@en

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@nl

prefLabel

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@en

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@nl

P1476

Role of afatinib in the treatment of advanced lung squamous cell carcinoma.

@en

P2093

Tiziana Vavalà

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer

Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far

Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Comprehensive genomic characterization of squamous cell lung cancers.

Erlotinib in previously treated non-small-cell lung cancer

P304

147-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/CPAA.S112715

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29225480

http://www.w3.org/2001/XMLSchema#string

P932

5709991

http://www.w3.org/2001/XMLSchema#string